An open label trial of OZ101 as an add-on therapy for the treatment of type 2 diabetes mellitus in patients on sulphonylurea therapy.
Phase of Trial: Phase II
Latest Information Update: 16 Jul 2019
Price : $35 *
At a glance
- Drugs OZ 101 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors OzStar Therapeutics
- 10 Dec 2018 Sydney site closed as of 05/12/2018, 22 patients enrolled in Bangalore India site. The site anticipates to recruit 8 additional patients prior to Christmas.
- 10 Dec 2018 Anticipated date last participant enrolled is 12/28/2018 as reported by Australian New Zealand Clinical Trials Registry
- 10 Dec 2018 Planned number of patients changed from 60 to 30 as Sydney site has been closed as of 05/12/2018 due to inability to find type 2 diabetes patients required for the study. Therefore, only India site will be recruiting 30 patients.